BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

MRK upcoming catalysts

Merck Sharp & Dohme LLC: 7 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (4 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 32 readout(s) and 19 FDA event(s). Subscribe to MRK (.ics).

Drugs: Pembrolizumab, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Tulisokibart, Paclitaxel, Cisplatin, Favezelimab/Pembrolizumab, Docetaxel, Gemcitabine, etoposide, Sacituzumab tirumotecan, Irinotecan, Carboplatin, Palbociclib, Sacituzumab Govitecan, Fluorouracil, Mitomycin C, doxorubicin, vinblastine, dacarbazine, cyclophosphamide, vincristine, prednisone/prednisolone, bleomycin, Trifluridine-Tipiracil, Methotrexate, Rosuvastatin, durvalumab, pemetrexed, Olaparib, nab-paclitaxel, capecitabine

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-20 est.P3Merck Sharp & Dohme LLC MRKNCT04634877 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer Endometrial Neoplasmsactive not recruiting990
2026-12-22 est.P1/P2Merck Sharp & Dohme LLC MRKNCT05468697 A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LIRenal Cell Carcinomaactive not recruiting60
2027-01-12 est.P3Merck Sharp & Dohme LLC MRKNCT05609968 Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell LungCarcinoma, Non-Small-Cell Lungactive not recruiting614
2027-01-15 est.P3Merck Sharp & Dohme LLC MRKNCT04199689 Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)Papillomavirus Infectionsactive not recruiting6033
2027-01-31 est.P3Merck Sharp & Dohme LLC MRKNCT04241185 Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-99Urinary Bladder Neoplasmsactive not recruiting520
2027-02-12 est.P2Merck Sharp & Dohme LLC MRKNCT03407144 Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)Hodgkin Lymphomaactive not recruiting340
2027-02-17 est.P2Merck Sharp & Dohme LLC MRKNCT07486960 Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)Psoriatic Arthritisactive not recruiting140

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-10-16FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2026-10-16: KEYTRUDA (BLA125514 SUPPL191)
2026-10-16FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDA QLEXApproved 2026-10-16: KEYTRUDA QLEX (BLA761467 SUPPL8)
2026-10-14FDA approvalapprovedMERCK SHARP DOHME MRKENFLONSIAApproved 2026-10-14: ENFLONSIA (BLA761432 SUPPL3)
2026-09-24FDA approvalapprovedMERCK SHARP DOHME MRKWELIREGApproved 2026-09-24: WELIREG (NDA215383 SUPPL13)
2026-09-21FDA approvalapprovedMERCK SHARP DOHME MRKWINREVAIRApproved 2026-09-21: WINREVAIR (BLA761363 SUPPL12)
2026-07-10FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2026-07-10: KEYTRUDA (BLA125514 SUPPL194)
2026-07-10FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDA QLEXApproved 2026-07-10: KEYTRUDA QLEX (BLA761467 SUPPL12)
2026-06-24FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2026-06-24: KEYTRUDA (BLA125514 SUPPL187)
2026-06-24FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDA QLEXApproved 2026-06-24: KEYTRUDA QLEX (BLA761467 SUPPL4)
2026-06-12FDA approvalapprovedMERCK SHARP DOHME MRKWELIREGApproved 2026-06-12: WELIREG (NDA215383 SUPPL15)
2026-06-12FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2026-06-12: KEYTRUDA (BLA125514 SUPPL192)
2026-06-12FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDA QLEXApproved 2026-06-12: KEYTRUDA QLEX (BLA761467 SUPPL9)
2026-04-24FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDA QLEXApproved 2026-04-24: KEYTRUDA QLEX (BLA761467 SUPPL3)
2026-02-10FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2026-02-10: KEYTRUDA (BLA125514 SUPPL186)
2026-02-10FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDA QLEXApproved 2026-02-10: KEYTRUDA QLEX (BLA761467 SUPPL2)
2026-01-27FDA approvalapprovedMERCK SHARP DOHME MRKNOXAFILApproved 2026-01-27: NOXAFIL (NDA205053 SUPPL18)
2026-01-27FDA approvalapprovedMERCK SHARP DOHME MRKNOXAFILApproved 2026-01-27: NOXAFIL (NDA205596 SUPPL21)
2025-11-21FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2025-11-21: KEYTRUDA (BLA125514 SUPPL188)
2025-11-21FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDA QLEXApproved 2025-11-21: KEYTRUDA QLEX (BLA761467 SUPPL1)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-28 est.P3Merck Sharp & Dohme LLC MRKNCT05239728 A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post NephrecCarcinoma, Renal Cellactive not recruiting1800
2026-10-19P3Merck Sharp & Dohme LLC MRKNCT06356311 A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Gastroesophageal Canceractive not recruiting473
2026-09-30P1/P2Merck Sharp & Dohme LLC MRKNCT06637423 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)Non-Muscle Invasive Bladder Cancercompleted35
2026-09-07P2Merck Sharp & Dohme LLC MRKNCT07176390 A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)Arthritis, Rheumatoidactive not recruiting185
2026-08-18 est.P2Merck Sharp & Dohme LLC MRKNCT06864169 A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)Gastrointestinal Canceractive not recruiting160
2026-08-12P3Merck Sharp & Dohme LLC MRKNCT06052059 A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)Ulcerative Colitisactive not recruiting1109
2026-08-10P1/P2Merck Sharp & Dohme LLC MRKNCT04626479 Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)Carcinoma, Renal Cellcompleted393
2026-08-03P3Merck Sharp & Dohme LLC MRKNCT07216482 A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)Hyperlipidemiacompleted996
2026-08-03P2Merck Sharp & Dohme LLC MRKNCT06465186 A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)Non-alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; NAFLD; Metabolic Dysfunction-associcompleted85
2026-07-23P1/P2Merck Sharp & Dohme LLC MRKNCT04626518 Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)Carcinoma, Renal Cellcompleted263
2026-06-15P3Merck Sharp & Dohme LLC MRKNCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent ChemoraCarcinoma, Non-Small-Cell Lungcompleted610
2026-06-08P2Merck Sharp & Dohme LLC MRKNCT04123366 Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous ReSolid Tumorscompleted333
2026-06-05P2Merck Sharp & Dohme LLC MRKNCT06721156 A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)Alzheimer Disease; Dementiaterminated369
2026-05-18P1/P2Merck Sharp & Dohme LLC MRKNCT04305054 Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) AdvancMelanomacompleted335
2026-04-24P3Merck Sharp & Dohme LLC MRKNCT04895358 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3Breast Neoplasmsactive not recruiting342
2026-04-21P2Merck Sharp & Dohme LLC MRKNCT05144841 A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)Relapsed or Refractory Diffuse Large B-Cell Lymphomacompleted140
2026-04-09P2Merck Sharp & Dohme LLC MRKNCT05612035 Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPDPulmonary Hypertension; Chronic Obstructive Pulmonary Diseaseactive not recruiting129
2026-04-02P2Merck Sharp & Dohme LLC MRKNCT06956235 Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)Hidradenitis Suppurativaactive not recruiting149
2026-03-12P3Merck Sharp & Dohme LLC MRKNCT06698042 A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)Lung Cancer; Non-Small Cell Lung Canceractive not recruiting67
2026-03-12P2Merck Sharp & Dohme LLC MRKNCT06036836 Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)Solid Tumor; Cutaneous Squamous Cell Carcinoma; Endometrial Cancercompleted163
2026-03-05P2/P3Merck Sharp & Dohme LLC MRKNCT06295809 A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)Carcinoma, Squamous Cell; Skin Neoplasmsterminated46
2026-02-04P3Merck Sharp & Dohme LLC MRKNCT05899049 A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination WitCarcinoma, Renal Cellactive not recruiting251
2026-02-04P3Merck Sharp & Dohme LLC MRKNCT04736706 A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination WitCarcinoma, Renal Cellactive not recruiting1688
2026-02-02P3Merck Sharp & Dohme LLC MRKNCT04586231 A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)Carcinoma, Renal Cellactive not recruiting747
2026-01-28P1/P2Merck Sharp & Dohme LLC MRKNCT03598608 Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MHodgkin Disease; Lymphoma, Non-Hodgkin; Lymphoma, B-Cellterminated137
2026-01-26P3Merck Sharp & Dohme LLC MRKNCT03924856 Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invBladder Cancercompleted907
2026-01-21P3Merck Sharp & Dohme LLC MRKNCT04210115 Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNEsophageal Squamous Cell Carcinoma (ESCC); Gastroesophageal Junction Carcinoma (GEJC); Esophageal Adcompleted703
2026-01-14P3Merck Sharp & Dohme LLC MRKNCT02684292 Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)Hodgkin Lymphomacompleted304
2025-12-29P2Merck Sharp & Dohme LLC MRKNCT05877547 A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)Non-alcoholic Fatty Liver Disease; Fatty Liver, Nonalcoholic; NAFLD; Nonalcoholic Fatty Liver Diseascompleted381
2025-12-22P3Merck Sharp & Dohme LLC MRKNCT04193215 V114 and Acute Otitis Media (V114-032/PNEU-ERA)Acute Otitis Media (AOM)completed7119
2025-12-05P1/P2Merck Sharp & Dohme LLC MRKNCT05342636 A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)Esophageal Squamous Cell Carcinoma (ESCC)completed90
2025-11-20P2Merck Sharp & Dohme LLC MRKNCT06664801 A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)Pulmonary Arterial Hypertensioncompleted164

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.